---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-25-000041"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:52:35.120218+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M

## Summary
- Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).
- 2025 revenue guidance narrowed to $1.5-$2.2B (high end cut $300M due to UK delivery timing shift to 2026).
- GAAP operating expenses expected $5.9-$6.1B, improved ~$400M; year-end cash ~$6B reiterated.
- Announced three FDA approvals (mNEXSPIKE for high-risk adults, Spikevax for children, mRESVIA for 18-59) and positive Phase 3 flu vaccine efficacy data.
- Restructuring: global workforce reduction of ~10%, targeting headcount under 5,000 by year-end.

## SEC filing metadata
- accession: 0001682852-25-000041
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/0001682852-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/mrna-20250801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-25-000041
- JSON: https://secwatch.observer/filing/0001682852-25-000041.json
- Plain text: https://secwatch.observer/filing/0001682852-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.